A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma

Agop Y. Bedikian, Jon Richards, Dmitri Kharkevitch, Michael B. Atkins, Eric Whitman, Rene Gonzalez

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Allovectin-7, a bicistronic plasmid encoding human leukocyte antigen-B7 and β-2 microglobulin formulated with a cationic lipid system, is an immunotherapeutic agent designed to express allogeneic major histocompatibility complex class I antigen upon intralesional administration. A phase 2 dose-escalation study (VCL-1005-208) was conducted to evaluate the safety and efficacy of Allovectin-7 in patients with metastatic melanoma. Eligible patients had stage III or IV metastatic melanoma recurrent or unresponsive to prior therapy, an Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients with brain or visceral (except lung) metastases, abnormal lactate dehydrogenase, or any lesion greater than 100 cm2 were excluded. Patients received six weekly intralesional injections followed by 3 weeks of observation and evaluation. Overall response was assessed using Response Evaluation Criteria in Solid Tumors guidelines. Patients with stable or responding disease were eligible to receive additional cycles of Allovectin-7. All 133 patients were evaluated for safety and 127 patients (2 mg, high dose) were evaluated for efficacy. Fifteen patients (11.8%, 95% confidence interval: 6.2-17.4) achieved an objective response with median duration of response of 13.8 months (95% confidence interval: 8.5, not estimable). A histological examination of tissue from two responding patients who had their lesions resected has shown no evidence of melanoma. Median time-to-progression in this study was 1.6 months. In conclusion, these results indicate that high-dose Allovectin-7 seems to be an active, well-tolerated treatment for selected stage III/IV metastatic melanoma patients with injectable cutaneous, subcutaneous, or nodal lesions.

Original languageEnglish (US)
Pages (from-to)218-226
Number of pages9
JournalMelanoma Research
Volume20
Issue number3
DOIs
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

Melanoma
Confidence Intervals
Intralesional Injections
Allovectin-7
Histocompatibility Antigens Class I
Patient Safety
HLA Antigens
Major Histocompatibility Complex
L-Lactate Dehydrogenase
Plasmids
Observation
Guidelines
Neoplasm Metastasis
Lipids
Safety
Lung
Skin
Injections
Brain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

Bedikian, Agop Y. ; Richards, Jon ; Kharkevitch, Dmitri ; Atkins, Michael B. ; Whitman, Eric ; Gonzalez, Rene. / A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. In: Melanoma Research. 2010 ; Vol. 20, No. 3. pp. 218-226.
@article{1497c954b6ab456b98b7b6f0bc2a63a6,
title = "A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma",
abstract = "Allovectin-7, a bicistronic plasmid encoding human leukocyte antigen-B7 and β-2 microglobulin formulated with a cationic lipid system, is an immunotherapeutic agent designed to express allogeneic major histocompatibility complex class I antigen upon intralesional administration. A phase 2 dose-escalation study (VCL-1005-208) was conducted to evaluate the safety and efficacy of Allovectin-7 in patients with metastatic melanoma. Eligible patients had stage III or IV metastatic melanoma recurrent or unresponsive to prior therapy, an Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients with brain or visceral (except lung) metastases, abnormal lactate dehydrogenase, or any lesion greater than 100 cm2 were excluded. Patients received six weekly intralesional injections followed by 3 weeks of observation and evaluation. Overall response was assessed using Response Evaluation Criteria in Solid Tumors guidelines. Patients with stable or responding disease were eligible to receive additional cycles of Allovectin-7. All 133 patients were evaluated for safety and 127 patients (2 mg, high dose) were evaluated for efficacy. Fifteen patients (11.8{\%}, 95{\%} confidence interval: 6.2-17.4) achieved an objective response with median duration of response of 13.8 months (95{\%} confidence interval: 8.5, not estimable). A histological examination of tissue from two responding patients who had their lesions resected has shown no evidence of melanoma. Median time-to-progression in this study was 1.6 months. In conclusion, these results indicate that high-dose Allovectin-7 seems to be an active, well-tolerated treatment for selected stage III/IV metastatic melanoma patients with injectable cutaneous, subcutaneous, or nodal lesions.",
author = "Bedikian, {Agop Y.} and Jon Richards and Dmitri Kharkevitch and Atkins, {Michael B.} and Eric Whitman and Rene Gonzalez",
year = "2010",
month = "6",
day = "1",
doi = "10.1097/CMR.0b013e3283390711",
language = "English (US)",
volume = "20",
pages = "218--226",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Bedikian, AY, Richards, J, Kharkevitch, D, Atkins, MB, Whitman, E & Gonzalez, R 2010, 'A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma', Melanoma Research, vol. 20, no. 3, pp. 218-226. https://doi.org/10.1097/CMR.0b013e3283390711

A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. / Bedikian, Agop Y.; Richards, Jon; Kharkevitch, Dmitri; Atkins, Michael B.; Whitman, Eric; Gonzalez, Rene.

In: Melanoma Research, Vol. 20, No. 3, 01.06.2010, p. 218-226.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma

AU - Bedikian, Agop Y.

AU - Richards, Jon

AU - Kharkevitch, Dmitri

AU - Atkins, Michael B.

AU - Whitman, Eric

AU - Gonzalez, Rene

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Allovectin-7, a bicistronic plasmid encoding human leukocyte antigen-B7 and β-2 microglobulin formulated with a cationic lipid system, is an immunotherapeutic agent designed to express allogeneic major histocompatibility complex class I antigen upon intralesional administration. A phase 2 dose-escalation study (VCL-1005-208) was conducted to evaluate the safety and efficacy of Allovectin-7 in patients with metastatic melanoma. Eligible patients had stage III or IV metastatic melanoma recurrent or unresponsive to prior therapy, an Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients with brain or visceral (except lung) metastases, abnormal lactate dehydrogenase, or any lesion greater than 100 cm2 were excluded. Patients received six weekly intralesional injections followed by 3 weeks of observation and evaluation. Overall response was assessed using Response Evaluation Criteria in Solid Tumors guidelines. Patients with stable or responding disease were eligible to receive additional cycles of Allovectin-7. All 133 patients were evaluated for safety and 127 patients (2 mg, high dose) were evaluated for efficacy. Fifteen patients (11.8%, 95% confidence interval: 6.2-17.4) achieved an objective response with median duration of response of 13.8 months (95% confidence interval: 8.5, not estimable). A histological examination of tissue from two responding patients who had their lesions resected has shown no evidence of melanoma. Median time-to-progression in this study was 1.6 months. In conclusion, these results indicate that high-dose Allovectin-7 seems to be an active, well-tolerated treatment for selected stage III/IV metastatic melanoma patients with injectable cutaneous, subcutaneous, or nodal lesions.

AB - Allovectin-7, a bicistronic plasmid encoding human leukocyte antigen-B7 and β-2 microglobulin formulated with a cationic lipid system, is an immunotherapeutic agent designed to express allogeneic major histocompatibility complex class I antigen upon intralesional administration. A phase 2 dose-escalation study (VCL-1005-208) was conducted to evaluate the safety and efficacy of Allovectin-7 in patients with metastatic melanoma. Eligible patients had stage III or IV metastatic melanoma recurrent or unresponsive to prior therapy, an Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients with brain or visceral (except lung) metastases, abnormal lactate dehydrogenase, or any lesion greater than 100 cm2 were excluded. Patients received six weekly intralesional injections followed by 3 weeks of observation and evaluation. Overall response was assessed using Response Evaluation Criteria in Solid Tumors guidelines. Patients with stable or responding disease were eligible to receive additional cycles of Allovectin-7. All 133 patients were evaluated for safety and 127 patients (2 mg, high dose) were evaluated for efficacy. Fifteen patients (11.8%, 95% confidence interval: 6.2-17.4) achieved an objective response with median duration of response of 13.8 months (95% confidence interval: 8.5, not estimable). A histological examination of tissue from two responding patients who had their lesions resected has shown no evidence of melanoma. Median time-to-progression in this study was 1.6 months. In conclusion, these results indicate that high-dose Allovectin-7 seems to be an active, well-tolerated treatment for selected stage III/IV metastatic melanoma patients with injectable cutaneous, subcutaneous, or nodal lesions.

UR - http://www.scopus.com/inward/record.url?scp=77952238515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952238515&partnerID=8YFLogxK

U2 - 10.1097/CMR.0b013e3283390711

DO - 10.1097/CMR.0b013e3283390711

M3 - Article

VL - 20

SP - 218

EP - 226

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 3

ER -